Social Determinants of Health and Survival on Brazilian Patients with Glioblastoma: a Retrospective Analysis of a Large Populational Database

Background: The majority of patients diagnosed with glioblastoma develop recurrent disease resulting in poor prognoses. The current study aimed to determine the survival rates of patients diagnosed with glioblastoma in Brazil accounting for the influence of age, treatment modalities, public and private practices, and educational level using a population-based national database.

Methods: Patients diagnosed with glioblastoma from 1999-2020 were identified from The Fundação Oncocentro de São Paulo database to create a retrospective cohort. Patients were described according to age, education level treatment modalities and medical practice. In a Cox proportional hazards model, controlled for confounding factors for overall survival, the hazard ratio and 95% CI of overall survival in adults was evaluated.

Findings: A total of 4,511 patients were included. The median lengths of survival for patients treated in the public and private settings were 8 and 17 months (p<0.001), respectively. Young patients had longer median overall survival (OS: 18 to 40 years, 41 to 60 years, 61 to 65 years, 66 to 70 years and over than 70 years was 22 months, 10 months, 6 months, 5 months, 4 months, respectively (p<0.001). In general, combined treatments were associated with higher median survival compared to monotherapy. The higher educational level, the higher median survival was observed (4 months for illiterate versus 14 months for university degree). In the multivariable analyses, the significant independent predictors for overall survival were practice setting, educational level, age and treatment modalities.

Interpretation: Public practice, older patients, less intensive treatment, and lower educational level were associated with worse survival outcomes in Brazilian glioblastoma patients.

Citing Articles

AI tool for predicting MGMT methylation in glioblastoma for clinical decision support in resource limited settings.

Restini F, Torfeh T, Aouadi S, Hammoud R, Al-Hammadi N, Starling M Sci Rep. 2024; 14(1):27995.

PMID: 39543155 PMC: 11564566. DOI: 10.1038/s41598-024-78189-6.

References

Curry Jr W, Carter B, Barker 2nd F . Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988-2004. Neurosurgery. 2010; 66(3):427-37. DOI: 10.1227/01.NEU.0000365265.10141.8E. View

Brown D, Himes B, Kerezoudis P, Chilinda-Salter Y, Grewal S, Spear J . Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro Oncol. 2018; 20(10):1374-1382. PMC: 6120360. DOI: 10.1093/neuonc/noy102. View

Liu E, Yu S, Sulman E, Kurz S . Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. J Neurooncol. 2020; 149(1):55-64. DOI: 10.1007/s11060-020-03572-y. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Melo S, Marta G, Yan M, Cruz C, Moraes F, Riera R . Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy. Ann Palliat Med. 2020; 9(5):3553-3561. DOI: 10.21037/apm-20-768. View

Rong X, Yang W, Garzon-Muvdi T, Caplan J, Hui X, Lim M . Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study. Cancer. 2016; 122(20):3157-3165. DOI: 10.1002/cncr.30160. View

Tseng J, Merchant E, Tseng M . Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. Surg Neurol. 2006; 66(3):258-63. DOI: 10.1016/j.surneu.2006.03.048. View

Philips Jr B, Belasco E, Markides K, Gong G . Socioeconomic deprivation as a determinant of cancer mortality and the Hispanic paradox in Texas, USA. Int J Equity Health. 2013; 12:26. PMC: 3639133. DOI: 10.1186/1475-9276-12-26. View

Hussain S, Lenner P, Sundquist J, Hemminki K . Influence of education level on cancer survival in Sweden. Ann Oncol. 2007; 19(1):156-62. DOI: 10.1093/annonc/mdm413. View

10.

Mukherjee D, Zaidi H, Kosztowski T, Chaichana K, Brem H, Chang D . Disparities in access to neuro-oncologic care in the United States. Arch Surg. 2010; 145(3):247-53. DOI: 10.1001/archsurg.2009.288. View

11.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

12.

Xie J, Yang S, Liu X, Zhao Y . Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status. Cancer Med. 2018; 7(8):3722-3742. PMC: 6089174. DOI: 10.1002/cam4.1688. View

13.

McAleenan A, Kelly C, Spiga F, Kernohan A, Cheng H, Dawson S . Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev. 2021; 3:CD013316. PMC: 8078495. DOI: 10.1002/14651858.CD013316.pub2. View

14.

Chandra A, Rick J, Dalle Ore C, Lau D, Nguyen A, Carrera D . Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus. 2018; 44(6):E16. PMC: 6105315. DOI: 10.3171/2018.3.FOCUS1852. View

15.

Massuda A, Hone T, Leles F, de Castro M, Atun R . The Brazilian health system at crossroads: progress, crisis and resilience. BMJ Glob Health. 2018; 3(4):e000829. PMC: 6035510. DOI: 10.1136/bmjgh-2018-000829. View

16.

Shavers V . Measurement of socioeconomic status in health disparities research. J Natl Med Assoc. 2007; 99(9):1013-23. PMC: 2575866. View

17.

Oronsky B, Reid T, Oronsky A, Sandhu N, Knox S . A Review of Newly Diagnosed Glioblastoma. Front Oncol. 2021; 10:574012. PMC: 7892469. DOI: 10.3389/fonc.2020.574012. View

18.

Ostrom Q, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017; 19(suppl_5):v1-v88. PMC: 5693142. DOI: 10.1093/neuonc/nox158. View

19.

Santos V, Marta G, Mesquita M, Mendoza Lopez R, Cavalcante E, Feher O . The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma. J Neurooncol. 2019; 143(1):95-100. DOI: 10.1007/s11060-019-03137-8. View

20.

Aizer A, Falit B, Mendu M, Chen M, Choueiri T, Hoffman K . Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014; 32(19):2025-30. PMC: 4879691. DOI: 10.1200/JCO.2013.54.2555. View